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Abstract
Background: Neuroblastoma is the most common extracranial solid tumor of childhood. The heterogeneous
microenvironment of solid tumors contains hypoxic regions associated with poor prognosis and chemoresistance.
Hypoxia implicates the actin cytoskeleton through its essential roles in motility, invasion and proliferation. However,
hypoxia-induced changes in the actin cytoskeleton have only recently been observed in human cells. Tropomyosins
are key regulators of the actin cytoskeleton and we hypothesized that tropomyosins may mediate hypoxic phenotypes.
Methods: Neuroblastoma (SH-EP) cells were incubated ± hypoxia (1 % O2, 5 % CO2) for up to 144 h, before examining
the cytoskeleton by confocal microscopy and Western blotting.
Results: Hypoxic cells were characterized by a more organized actin cytoskeleton and a reduced ability to degrade
gelatin substrates. Hypoxia significantly increased mean actin filament bundle width (72 h) and actin filament length
(72–96 h). This correlated with increased hypoxic expression and filamentous organization of stabilizing tropomyosins
Tm1 and Tm2. However, isoform specific changes in tropomyosin expression were more evident at 96 h.
Conclusions: This study demonstrates hypoxia-induced changes in the recruitment of high molecular weight
tropomyosins into the actin stress fibres of a human cancer. While hypoxia induced clear changes in actin organization
compared with parallel normoxic cultures of neuroblastoma, the precise role of tropomyosins in this hypoxic actin
reorganization remains to be determined.
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Background
Neuroblastoma is the most common extracranial solid
tumor of childhood. These neoplasms derive from imma-
ture cells of the sympathetic nervous system (SNS) and
can present at any SNS structure, most commonly in and
around the adrenal glands [1, 2]. Over 90 % of patients are
younger than 5 years at diagnosis and over half present
with metastatic spread, predominately to the bone marrow
and bone [3, 4]. While overall survival for stage 1 and 2
patients is 96.2 % and 88.6 %, respectively, overall survival
for high-grade, stage 4 patients remains low at 22.4 % [5].
Solid tumors are heterogeneous, complex structures that
must be analysed in the context of their microenvironment
[6]. Structurally and functionally poor quality tumor vascula-
ture leads to regions of low oxygen (O2) perfusion referred
to as hypoxia [7]. Prognoses are made worse by hypoxic
microenvironments, which create genetic instability funda-
mental to tumor progression [8] and increase neuroblastoma
resistance to radiotherapy and standard chemotherapies
[9–12]. The actin cytoskeleton is essential for various hyp-
oxic phenotypes, including altered motility and invasion.
However, until now, no studies have examined the effect of
hypoxia on the actin cytoskeleton of neuroblastoma.
The aggressive hypoxic phenotype of neuroblastoma is
well documented. Over a decade ago, Ginis and Faller [13]
observed that Kelly neuroblastoma cells increased their in-
vasiveness and decreased their adhesion to endothelium
when treated to hypoxic conditions,, indicating a pro-
metastatic phenotype. Hypoxia-fostered malignancies are
worsened by neuroblastoma dedifferentiation in vitro and
in vivo, with reversion to an immature and neural crest-like
phenotype [14]. Such dedifferentiation is associated with in-
creased tumor heterogeneity and aggressiveness [14, 15].
Moreover, the neuroblastoma transcriptome and proteome
are dramatically altered by hypoxia toward malignant and
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metastatic profiles. Hypoxia upregulates the expression of
genes associated with growth, survival and drug resistance
[16] and induces a pro-metastatic gene program [17].
Hypoxia-inducible factor (HIF) transcription factors are
believed to be the master transcriptional regulators of the
hypoxic response [18, 19]. HIFs are heterodimeric tran-
scription factors composed of an O2-regulated α subunit
and a constitutively expressed β subunit [20]. Under con-
ventional tissue culture O2 tensions (20 % O2), referred to
as normoxia, HIF-α subunits are rapidly hydroxylated, ubi-
quitinated and proteasomally degraded [21–23]. At 1 % O2,
HIF-1α and HIF-2α subunits are stabilized and translocate
to the nucleus [24]. Whether caused by hypoxia or onco-
genic mutations, increased HIF levels are largely associated
with poor prognoses in a variety of cancers [18]. In neuro-
blastoma, HIF-2α predicts poor patient outcome, while
HIF-1α has been associated with a favorable prognosis [25].
Intriguingly, hypoxia-induced chemoresistance is HIF-1α-
dependent [11, 12]. More recently, the sonic hedgehog
signaling pathway has been implicated in HIF-1α-mediated
proliferation and invasion of neuroblastoma cells [26].
Actin is a core component of the eukaryotic cytoskel-
eton. It is well established that changes in actin
organization and the levels of its binding proteins are es-
sential to the cancer cell phenotype (reviewed in [27, 28]).
In fact, the actin cytoskeleton is essential for a variety of
processes hijacked or subverted by hypoxic cancer cells.
These include proliferation, invasion, motility, adhesion
and apoptosis [28–32]. A recent study found that hypoxia
led to HIF-1α-dependent actin filament rearrangement in
mouse L929 fibrosarcoma cells [33]. However, to our
knowledge, no studies have previously examined the role
of the actin cytoskeleton in hypoxic human cancer
phenotypes.
The tropomyosin family of proteins are involved in
most, if not all, actin cytoskeletal functions [34]. Tropo-
myosins exist as rod-like coiled coil dimers that form
head-to-tail polymers [35] and wrap along the major
grooves of most actin filaments. Four genes, TPM1-4,
encode over 40 mammalian isoforms through splicing
and alternative promoters. High (HMW) and low mo-
lecular weight (LMW) isoforms correspond to ~284 and
247 amino acids, respectively [36]. Tropomyosins con-
tribute to the spatial and temporal regulation of the
actin cytoskeleton in an isoform-specific manner, by
regulating actin’s association with a plethora of actin-
binding proteins [34]. Interestingly, tropomyosins are
implicated in the pathogenesis of cancer. HMW iso-
forms are consistently down-regulated in transformed
cells, while malignant cells display an increased reli-
ance on LMW isoforms [37]. We have previously ob-
served consistent down-regulation of HMW isoforms
(Tm1, Tm2 and Tm3) and an increased reliance on
LMW isoforms (Tm5NM1/2 and Tm4) in all profiled
neuroblastoma and melanoma cell lines, as well as
transformed primary BJ fibroblasts [38].
We hypothesized that tropomyosins may facilitate the
hypoxic phenotypes of cancers such as neuroblastoma
by driving changes in the actin cytoskeleton. We there-
fore aimed (1) to characterize the hypoxic phenotype by
observing changes in neuroblastoma cell proliferation
and invasion, and (2) to examine hypoxia-induced
changes in the actin cytoskeleton, including tropomyosin
isoform expression and localization.
In this study we have demonstrated hypoxia-induced
changes in tropomyosin expression and localization in a
human cancer. Changes in actin organization characteris-
tic of reversion of the transformed phenotype are induced
by hypoxia at 72 h in neuroblastoma. This correlates with
expected isoform-specific changes in tropomyosin
localization. However, isoform specific changes in tropo-
myosin expression are more evident at 96 h. Hypoxia in-
duces clear changes in actin organization compared with
parallel normoxic cultures of neuroblastoma. However,
the role tropomyosins might play in driving this hypoxic
actin reorganization remains to be further elucidated.
Methods
Cell culture
SK-N-SH-EP (SH-EP) human neuroblastoma cells [39, 40]
were a generous gift from Children’s Hospital Westmead.
STR fingerprinting was performed to confirm the cell
line’s identity. SH-EP were maintained in growth media
containing Dulbecco’s modified Eagle’s medium (DMEM)/
high glucose (4.5 g/L), L-glutamine (4.0 mM) and sodium
pyruvate (4.0 mM) (HyClone-Thermo Scientific, UT,
USA), supplemented with 10 % v/v fetal bovine serum
(FBS) (Gibco-Life Technologies, NY, USA). Cells main-
tained at 37 °C in humidified, normoxic 5 % CO2/95 % air
incubator (~20 % O2). All replicate experiments con-
ducted within 6 passages. All studies reported in this
manuscript were in vitro cell based studies using human
cancer cell lines that are commercially available.
Hypoxic incubation
In neuroblastoma, metabolic hypoxia occurs below
8–10 mmHg O2 (approx. 1.1–1.3 % O2) [41]. To induce
hypoxia, cells were placed inside a modular incubator
chamber (Billups-Rothenberg, CA, USA) and flushed with
1 % O2/5 % CO2/94 % N2 gas (BOC Australia, NSW,
AUS) for 8 mins at 25 L/min. The sealed chamber was
incubated at 37 °C and flushing was repeated every 24 h.
Cell proliferation
Cells were seeded in 100 mm plates (Costar-Corning,
NY, USA) at 9.2 × 104/10 mL media and incubated at
37 °C overnight, before incubating ± hypoxia for 24–144 h.
Cells were harvested with trypsin-EDTA (Gibco-Life
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Technologies, NY, USA) and resuspended in growth
media. Live cells counted using Countess® Automated
Cell Counter after mixing 1:1 with 0.4 % w/v trypan
blue (Invitrogen, CA, USA).
Invasion assays
QCM Gelatin Invadopodia Assay (Millipore, MA, USA)
performed as per manufacturer’s instructions in 8-well
Lab-Tek® chamber slides (Nunc, IL, USA). Briefly, cells
seeded at 1.6 × 104/well onto GFP-tagged gelatin to
examine invadopodial matrix-degradation. After 72–96 h ±
hypoxia, cells were fixed and stained with kit-supplied
DAPI nucleic acid stain and filamentous actin-binding
TRITC-phalloidin. Coverslips mounted with ProLong
Gold Antifade Reagent (Invitrogen, OR, USA) and
cells visualized using an Axioskop 40 epifluorescent
microscope (20× objective) (Zeiss, Göttingen, Germany).
Five fields of view obtained per condition. Gelatin degrad-
ation, cell area and cell counts quantified using ImageJ
(V1.46; NIH).
Actin cytoskeleton and tropomyosin organization
Cells seeded at 9.2 × 103/mL media on coverslips (Carl
Zeiss Microscopy, NY, USA) and incubated overnight in
normoxia. Cells then incubated ± hypoxia for 48–96 h
(actin cytoskeleton) or 72 h (tropomyosin). Cells fixed in
4 % w/v paraformaldehyde (PFA) in phosphate-buffered
saline (PBS) for 15 mins, then washed thrice in PBS. All
staining performed at room temperature (RT), as below.
Actin and tropomyosin immunofluorescence staining
For actin filament staining, cells were permeabilized with
0.1 % v/v TritonX-100 for 5 mins, washed thrice in PBS,
blocked in 0.5 % w/v bovine serum albumin (BSA) in
PBS for 1 h, incubated with TRITC-phalloidin (1:1,000;
Sigma-Aldrich) in 0.5 % w/v BSA and washed thrice in
PBS. For anti-tropomyosin staining, cells were perme-
abilized with −80 °C methanol for 15 mins, washed
thrice in PBS, blocked with 2 % v/v FBS in PBS for 30
mins, incubated with primary tropomyosin isoform-
specific antibody for 2 h diluted in 2 % v/v FBS as per
Table 1, washed thrice in PBS, incubated with appropri-
ate Alexa555- or Alexa488-conjugated secondary anti-
body for 1 h in the dark, diluted in 2 % v/v FBS as per
Table 1, and washed thrice in PBS. All coverslips then
incubated with DAPI nucleic acid stain (1:10,000) in PBS
for 1 min, washed thrice in PBS and mounted onto
microscope slides using ProLong Gold Antifade Reagent.
Single z-plane images obtained using an SP5 2P STED
confocal microscope (40× oil objective) (Leica Microsys-
tems, Wetzlar, Germany). Actin filament bundle width
and length were quantitated using a linear-feature detec-
tion algorithm developed in collaboration with the
CSIRO and previously described [42].
Table 1 Primary and secondary antibodies
Name 1° /2° Target Dilution Species Commercial availability Ref.
α/9d 1° Tm1, 2, 3, 5a*, 5b*, 6* WB/IF: 1:500 Mouse monoclonal (IgG2b κ;
clone 15D12.2
– [79]
γ/9d 1° Tm5NM1/2 WB/IF: 1:500 Mouse monoclonal (IgG2b κ;
clone 2G10.2)
– [79]
WD4/9d 1° Tm4 WB/IF: 1:500 Rabbit polyclonal Millipore [80]
CG1 1° Tm1 IF: 1:50 Mouse monoclonal (IgG) – [79]
CG3 1° Tm5NM1-11 WB/IF: 1:150 Mouse monoclonal (IgM) – [79]
CGβ6 1° Tm2, 3 IF: 1:150 Mouse monoclonal (IgM) – [79]
Tm311 1° Tm1, 2, 3, 6*, Br1*, plus α-,β-, γ-muscle* IF: 1:500 Mouse monoclonal (IgG1),
clone TM311
Sigma-Aldrich [81]
C4 Actin 1° Actin WB: 1:5000 Mouse monoclonal, (IgG1κ;
clone C4)
Millipore [82]
α-actinin 1° α-actinin 1-4 WB: 1:200 Rabbit polyclonal (H-300) Santa Cruz Biotechnology [83]
HIF-1α 1° HIF-1α WB: 1:500 Mouse monoclonal (IgG1;
clone 54)
BD Biosciences [20]
HIF-2α 1° HIF-2α WB: 1:500 Rabbit polyclonal Novus Biologicals [84]
GAM-HRP 2° Mouse (H + L) WB: 1:5000 Goat polyclonal Bio-Rad [85]
GAR-HRP 2° Rabbit (H + L) WB: 1:5000 Goat polyclonal Bio-Rad [85]
Alexa Fluor® 555 GAM 2° Mouse (H + L) IF: 1:1000 Goat polyclonal Molecular Probes [86]
Alexa Fluor® 488 GAR 2° Rabbit (H + L) IF: 1:1000 Goat polyclonal Molecular Probes [86]
*Tropomyosin isoforms not expressed by SH-EP (Stehn et al., unpublished data). Those antibodies not commercially available were generated in-house
WB Western blot, IF immunofluorescence, 1° primary antibody, 2° secondary antibody, GAM goat anti-mouse, GAR goat anti-rabbit, HRP horseradish peroxidase, H
heavy chain of IgG, L light chain of IgG
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Protein expression analysis
Cells were seeded in 100 mm plates at 9.2 × 104/10 mL,
incubated overnight in normoxia at 37 °C, before incu-
bating ± hypoxia for 48–144 h. Cells were harvested
using trypsin-EDTA, pelleted by centrifugation
(1,200 rpm, 4 °C, 10 mins) and stored at −80 °C unless
used immediately. Cells lysed in 100 μl/4 × 105 cells of
radioimmunoprecipitation assay (RIPA) buffer (6.67 mL
1.5 M Tris pH 8.0, 2 mL NP-40, 1 g deoxycholic acid,
1 mL 20 % w/v SDS, 1.752 g NaCl made to 200 mL with
ddH2O) containing complete protease inhibitor cocktail
(Roche Applied Science, IN, USA). For HIF-1/2α immu-
noblots, plates were transferred immediately to ice,
rinsed with ice-cold PBS containing complete protease
inhibitor cocktail and mechanically scraped using
50–100 μl RIPA buffer containing protease inhibitor
cocktail. All lysates incubated on ice for 20 mins before
centrifugation (16,100 × g, 4 °C, 10 mins). Supernatants
transferred to new tubes. Total protein concentration
estimated using bicinchoninic acid (BCA) protein
assay (Thermo Scientific, IL, USA) and/or Direct
Detect™ Spectrometer (EMD Millipore Corporation,
MA, USA), as per manufacturers’ instructions.
Western blotting
Lysates mixed with 4× Laemmli sample buffer (62.5 mM
Tris–HCl pH 6.8, 10 % v/v glycerol, 1 % v/v SDS,
0.005 % w/v bromophenol blue, 355 mM 2-
mercaptoethanol) in PBS to give total protein/lane of
6–10 μg (tropomyosin) or 25–35 μg (HIF-1α/2α).
Samples heated for 5 mins at 95 °C and loaded onto
12.5 % (tropomyosin) or 8 % (HIF-1/2α) v/v SDS-
PAGE gels with Precision Plus Protein™ standards
(Bio-Rad, CA, USA). Gel electrophoresis performed in
running buffer (1.0 L milli-Q H2O, 2.9 g Tris, 14.5 g
glycine, 1 g SDS) at 120 V (Mini-PROTEAN® Tetra
Cell; Bio-Rad, CA, USA). Proteins transferred to
Immobilon-P polyvinylidene difluoride (PVDF) mem-
branes (Millipore, MA, USA) in transfer buffer (1.6 L
milli-Q H2O, 400 mL methanol, 5.8 g Tris, 29 g
glycine) for 2 h at 80 V on ice.
Membranes blocked in 5 % w/v skim milk (SM) in
Tris-buffered saline containing 0.1 % v/v Tween-20
(TBST) for 30 mins at RT. Membranes then incubated
with primary antibody diluted as per Table 1 in 2 % w/v
SM/TBST for 2 h at RT with constant agitation (tropo-
myosin and actin) or in 5 % w/v SM/TBST overnight at
4 °C (HIF-1/2α). Membranes washed thrice in TBST and
incubated with appropriate HRP-conjugated secondary
antibody (Table 1) in 2 % v/v SM/TBST for 1 h at RT.
Membranes washed thrice in TBST, incubated with en-
hanced chemiluminescence (ECL) reagents (GE Health-
care, Amersham, UK) and visualized using medical
radiographic film (Fuji Medical, Tokyo, Japan) or
ImageQuant™ LAS-4000 (GE Healthcare, Munich,
Germany). Densitometry performed on ImageJ. All
results normalized to C4 actin loading control.
Statistical analysis
Statistical analysis was conducted using two-sided t-
tests, or two-way ANOVA when testing three or more
means (GraphPad Prism V6.0). Results are mean ± SEM.
P <0.05 was considered statistically significant.
Results
Hypoxia increases the levels of HIF-1α and HIF-2α in
SH-EP neuroblastoma cells
HIF-1α and HIF-2α are commonly used markers of cel-
lular hypoxia and these were used to confirm induction
of hypoxia. Expression levels of both HIF-1α and HIF-
2α increased as early as 8 h following hypoxic incubation
compared with normoxic control cells (Additional file 1:
Figure S1). HIF-1α levels increased from 8 to 144 h
hypoxia, while hypoxia-induced HIF-2α expression
peaked at 96 h.
Neuroblastoma proliferation is increased by hypoxia
Aggressive cancer phenotypes are characterised by
increased cellular proliferation. Given that a dynamic
actin cytoskeleton is required for proliferation and the
transcription factor HIF-2α promotes growth, we inves-
tigated the impact of hypoxia on SH-EP cell prolifera-
tion. SH-EP were cultured in normoxic and hypoxic
conditions for 24–144 h and cell number was deter-
mined using trypan blue exclusion. Hypoxic cell counts
were significantly increased at 72 and 120 h when nor-
malized to parallel normoxic cell cultures (P = 0.007 and
P = 0.01, respectively; Fig. 1a). Following confirmation of
physiological hypoxia at the abovementioned timepoints
(8–144 h), we proceeded to examine other aspects of the
hypoxic neuroblastoma phenotype.
Neuroblastoma cell invasiveness is reduced by hypoxia
Cellular invasiveness was measured by a QCM invadopo-
dia assay, which examined degradation of a fluorescent
gelatin matrix while controlling for cell number and size.
DAPI images (Fig. 1b) were thresholded to provide cell
counts (Fig. 1c), while thresholding TRITC-phalloidin
images (Fig. 1d) provided cell area values (Fig. 1e). Thresh-
olding GFP images (Fig. 1f) provided matrix degradation
areas (Fig. 1g). Hypoxia significantly reduced gelatin
degradation per cell area at 72 h (Fig. 1h), though no
significant difference was observed at 96 h (Fig. 1i).
Hypoxia promotes a more organized actin cytoskeleton
A dynamic actin cytoskeleton is fundamental to cell
migration and invasion. We therefore examined actin
cytoskeletal organization to understand the reduction in
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matrix degradation observed at 72 h hypoxia. Normoxic
cells stained with TRITC-phalloidin, which binds to fila-
mentous actin, displayed a disordered actin cytoskeleton
(Fig. 2a, b), while hypoxic cells displayed a strong
increase in actin cytoskeletal organization (Fig. 2c, d). In
particular, hypoxia consistently increased the number of
parallel actin filament bundles per cell. The actin-binding
















































































Fig. 1 Hypoxia alters the behavior of SH-EP neuroblastoma cells. a SH-EP cells were grown in normoxic (20 % O2) and hypoxic conditions (1 % O2) for
24–144 h. Hypoxic cell viability normalized to normoxic controls (dashed line through 1). b-i Representative images of a chamber slide (8-well) coated
with an extracellular matrix mimic, GFP-tagged gelatin, seeded with 1.6 × 104 SH-EP/well. After 72–96 h ± hypoxia, cells fixed in methanol and stained
with DAPI and TRITC-phalloidin. Five fields of view (20× objective) were obtained for each well using a widefield microscope and images
imported into Image J for analysis. DAPI nuclear counts (b, c) provided cell numbers. Thresholding on phalloidin (d, e) and the absence
of GFP (f, g) provided cell and matrix degradation areas, respectively. Hypoxia resulted in decreased gelatin degradation per cell area at
72 h (h), although no significance was observed at 96 h (i). 1,000+ cells analysed per timepoint. Data is mean ± SEM; n = 4 (a), n = 3 (b-i).
* P < 0.05, ** P <0.01 (t-test). Scale bar = 50 μm
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enhances the invasive potential of cancer cells [44] and is
associated with poor prognosis in a variety of tumors
[45, 46]. For these reasons we examined α-actinin expres-
sion as a potential explanation for increased parallel
bundles of actin filaments with hypoxia. However, no
statistically significant change in expression was observed
between normoxic and hypoxic incubations of up to 144 h
(data not shown).
Using a linear-feature detection algorithm [42] we
quantitated various cytoskeletal parameters, including
actin filament bundle width and length (Fig. 2e–g).
Mean actin filament bundle width was significantly
increased by 72 h hypoxic incubation (Fig. 2e). Actin
filament length per cell (AFLC; Fig. 2f ) and per cell
area (AFLA; Fig. 2g) were significantly increased by
72–96 h hypoxia. The effect of hypoxia on AFLC and
AFLA was significant (P <0.0001, 2way ANOVA).
Expression of HMW tropomyosin isoforms, Tm1 and Tm2,
are altered by hypoxia
Due to the ‘master regulatory’ role of tropomyosins in the
actin cytoskeleton [34], changes in tropomyosin expres-
sion and localization could provide mechanistic insight
into our observed hypoxia-induced reorganization of actin
filaments. Clear changes were observed in HMW
tropomyosin levels in hypoxic SH-EP cells compared
with normoxic controls. HMW isoforms Tm1, Tm2
and Tm3 were detected by immunoblotting with the
α/9d antibody (Fig. 3a). Tm1 expression increased
significantly over normoxic controls with 72–96 h
hypoxia (Fig. 3b), while Tm2 levels increased signifi-
cantly above normoxia after 96 h hypoxia (Fig. 3c).
Although hypoxic Tm3 expression trended upward





























































Normoxia (20% O2) 
Hypoxia (1% O2) 
Fig. 2 Hypoxia leads to a more ordered actin cytoskeleton. SH-EP cells were grown in normoxia (20 % O2) or hypoxia (1 % O2) for 72 – 96 h. Coverslips
were fixed with 4 % PFA and stained with TRITC-phalloidin and DAPI. Single z-plane images were obtained by confocal microscopy. Linear feature
detection software was used to quantitate actin cytoskeletal organization. a-d Representative linear detection after 72 h ± hypoxia. Hypoxia visibly
increases the number of actin filament bundles known as stress fibres (b vs. d). Scale bar = 50 μm, or 5 μm in inset. e Hypoxia increases mean actin
filament bundle width at 72 h. f Hypoxia increases total actin filament length per cell number (AFLC) and (g) per cell area (AFLA). Data is mean ± SEM
(n = 3). 650+ cells analysed per timepoint. ** P <0.01, *** P <0.0001 (t-test). †AFLA is dimensionless, with [length (pixels)]/[area (pixels)]
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Hypoxia increases HMW tropomyosin-containing filaments
Tropomyosins may modulate the actin cytoskeleton in
an isoform-specific manner through changes in their
intracellular distribution [34]. Cells incubated with anti-
bodies that detect HMW tropomyosin isoforms (Tm1/2/3)
displayed an increase in filamentous structures at
72 h hypoxia (Fig. 3g, h) compared with normoxia
(Fig. 3e, f ). To better discern the role of individual
isoforms, we stained for Tm2/3 (CGβ6 antibody).
More Tm2/3-containing filaments were observed in
hypoxia (Fig. 3k, l) compared to normoxia (Fig. 3i, j).
Expression and intracellular organization of LMW
tropomyosin isoforms are unaltered by hypoxia
Hypoxia did not induce statistically significant changes
in expression of the LMW isoforms Tm4 (Fig. 4a, d),
Tm5NM1/2 (Fig. 4b, e), nor Tm5NM1-11 (Fig. 4c, f ).
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Fig. 3 Hypoxia alters the expression and localization of HMW tropomyosins. a Normoxic (N) and hypoxic (H) SH-EP lysates were separated by
SDS-PAGE. Representative Western blot stained with α9d antibody, which detects HMW tropomyosin isoforms Tm1, Tm2 and Tm3. Actin used
loading control. Densitometry values were normalized to normoxic levels (dashed line) for Tm1 (b), Tm2 (c) and Tm3 (d) expression. Results are
mean ± SEM; n = 3–4, * P <0.05, ** P <0.01 (t-test). e-l SH-EP cells were grown for 72 h ± hypoxia, fixed, permeabilized and incubated with Tm311
and CGβ6 antibodies to detect HMW isoforms Tm1/2/3 (e-h) and Tm2/3 (e-h), respectively. Cells then incubated with Alexa555-tagged goat anti-mouse
and single z-plane images obtained by confocal microscopy. Hypoxia increased filamentous organization of Tm1/2/3 (f vs. h) and Tm2/3 (j vs. l) compared
to normoxic control cells. Independent experiments (Tm311, n= 2; CGβ6, n= 5). Scale bar = 50 μm, 10 μm in inset
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Fig. 4 LMW Tropomyosin expression and localization are unaltered by hypoxia. Normoxic (N) and hypoxic (H) SH-EP lysates were separated by
SDS-PAGE and immunoblotted with a WD4/9d, b γ9d and c CG3 antibodies to examine expression of LMW isoforms Tm4, Tm5NM1/2
and Tm5NM1-11, respectively. Actin used as loading control (d-f) Densitometry was normalized to actin, before expressing hypoxic levels
relative to normoxic values (dashed line). Hypoxia did not significantly alter the expression of these LMW isoforms. Results are mean ±
SEM; n = 4. g-n SH-EP cells grown for 72 h ± hypoxia were fixed, permeabilized and incubated with γ9d to detect Tm5NM1/2 (g-j) and
WD4/9d to detect Tm4 (k-n). Cells then incubated with Alexa555-tagged goat anti-mouse or Alexa488-tagged goat anti-rabbit, respectively. Hypoxia
did not alter the intracellular organization of Tm5NM1/2 (h vs. j) nor Tm4 (l vs. n). Independent experiments (γ9d, n = 2; WD4/9d, n = 3).
Scale bar = 50 μm, 10 μm in inset
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organization were observed for Tm5NM1/2 (Fig. 4g–j)
and Tm4 (Fig. 4k–n).
Discussion
Given the essential roles of the actin cytoskeleton in
aggressive hypoxic phenotypes, it is surprising that the
actin cytoskeleton as a mediator of the hypoxic response
has remained largely unexplored until recently [33].
Few studies have examined the effect of hypoxia on
neuroblastoma proliferation. However, our observed in-
crease in hypoxic SH-EP proliferation is consistent with
a documented marginal increase in SH-EP cell number
after 48 h hypoxia [47]. We offer two theories to explain
our observation. First, HIF-2α enhances the activity of
the oncogenic transcription factor, c-Myc [48], which in-
creases cell proliferation by driving the G1/S cell cycle
transition [49]. Therefore, hypoxic induction of HIF-2α
should promote cell proliferation. Second, hypoxic
BE(2)C cells (72 h) induced the expression of both
growth factors and growth factor receptors, including
VEGF, IGF2, NRP1 and NGFR [16]. Hypoxia might
therefore induce autocrine growth and survival loops
that drive proliferation.
It is known that 72 h hypoxia induces a ‘fibroblastoid’
phenotype in neoplastic cells of epithelial origin [50].
This suggests involvement of the actin cytoskeleton—a
key determinant of cellular morphology—in the hypoxic
phenotype. A dynamic actin cytoskeleton is necessary
for enhanced migration and invasion [28] and it is
likely that our observed hypoxia-induced strengthen-
ing of actin cytoskeletal organization—increased actin
filament bundle width and length—led to reduced
actin dynamics.
Our observation that hypoxia reduced SH-EP cell
invasiveness is in contrast to a recent study where
hypoxia significantly increased BE(2)C invasion through
Matrigel-coated membranes [51]. However, hypoxia was
mimicked using deferoxamine mesylate and the invasive
phenotype was examined after 24 h hypoxia. Hypoxia
also increased neuroblastoma Kelly cell invasion through
Matrigel-coated membranes after treating cells to 24–48 h
hypoxia [13]. However, these cells were re-oxygenated
during the invasion assay. In contrast to SH-EP, which
reportedly contain no MYCN mRNA [52], all cell lines
displaying increased hypoxic invasiveness were MYCN-
amplified. This suggests hypoxia-induced invasion is cell-
line-specific and might implicate MYCN status.
The tropomyosin family of actin-associating proteins
are known to interact with and regulate actomyosin
structures, including actin filament stress fibres. Hypoxia
induced the expression of 35 kD and 36.5 kD HMW
tropomyosins in porcine pulmonary arterial epithelial
cells (PAEC) [53] and it is possible that up-regulated 34
kD and 36 kD proteins in hypoxic human and bovine
PAEC were also HMW tropomyosins [54, 55]. However,
mammalian evidence of hypoxia-induced tropomyosin
synthesis has until now been restricted solely to endo-
thelial cells.
Hypoxia starves cells of energy and a concomitant
reduction in protein synthesis is required to maintain es-
sential housekeeping functions. This reversible reduction
in overall protein synthesis is HIF-independent [56, 57].
Increased Tm1 and Tm2 levels after 3–4 days hypoxia
suggests these proteins must serve a critical, protective
role against hypoxic stress, analogous to the induction of
heat-shock proteins in hyperthermia [58]. The HMW
isoforms Tm1 and Tm2 increase the stability of actin
stress fibres [59] and partially protect actin filaments
from the severing actions of gelsolin [60, 61]. Moreover,
Tm1 and Tm2 display tumor suppressor activity in a
range of transformed and tumor cell lines [62–67]. As a
dynamic actin cytoskeleton is required for migration and
invasion, increased Tm1 and Tm2 expression, and their
recruitment to actin filaments, can largely explain the
reduced SH-EP invasion at 72 h hypoxia. Presumably,
this prevents the energy expenditure associated with
actin dynamics. Reduced actin dynamics and induction
of tumor suppressor proteins is in stark contrast to the
entire notion of an aggressive hypoxia phenotype. It is
therefore interesting that expression of these tumor-
suppressor isoforms decreased below normoxic levels at
144 h hypoxia (data not shown). We postulate that
chronically hypoxic SH-EP might become permissive of
the archetypal aggressive phenotype.
The structural and spatial organization of the actin
cytoskeleton is highly sensitive to reactive oxygen species
(ROS), such as hydrogen peroxide (H2O2) [68]. In
particular, ROS exposure results in a net increase of free
barbed ends and a dramatic increase in actin
polymerization [69]. More recently, oxidation of non-
muscle actin was shown to result in depolymerization of
actin filaments and a complete loss of polymerizability
[70]. As hypoxia is known to increase intracellular ROS,
primarily by the mitochondria [71–73], increased ex-
pression of Tm1 and Tm2 may represent an attempt to
protect the actin cytoskeleton from oxidative stress. In
addition, exposure of human endothelial cells to the
ROS, H2O2, induced ERK-mediated phosphorylation of
Tm1, followed by the rapid colocalization with actin and
stress fibres [74]. Therefore, the protection afforded by
HMW tropomyosins may be a result of increased
expression and posttranslational modification that
increases their association with the hypoxic actin
cytoskeleton.
Altered expression of tropomyosins in hypoxic neuro-
blastoma cells may involve epigenetic alterations to
HMW promoter regions. The TPM1 gene (encoding
Tm2) is silenced in metastatic breast and colon cancer
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cell lines by promoter hyper-methylation. Treatment of
these cells with the de-methylating agent 5-aza-2’-deoxy-
cytidine (5-aza-dC) reactivated TPM1 gene expression
[75]. Another study demonstrated 5-aza-dC treatment in-
duced up-regulation of TPM2 (encoding Tm1), but not
TPM1, in metastatic breast cancer cells [76], while TPM1
and TPM2 were both up-regulated in demethylated fibro-
sarcoma cells [77]. As hypoxia induces global hypo-
methylation [78], we postulate that hypoxia leads to the
‘de-repression’ of tropomyosin expression. Interestingly,
most pathways that repress tropomyosin expression affect
HMW, but not LMW, tropomyosin isoforms (reviewed in
Gunning et al. [34]). HMW isoforms contain the 1a exon,
while LMW isoforms contain the 1b exon. As cancer leads
to hyper-methylation of CpG islands [78], we performed a
qualitative examination of the CpG islands flanking the 1a
and 1b exons. This revealed a substantially higher CG con-
tent flanking the HMW 1a exon over the LMW 1b exon.
This suggests exon 1a-containing HMW tropomyosins may
be more susceptible to a hypoxic de-repression of gene
expression.
Conclusions
Hypoxic induction of the tumor-suppressor isoforms, Tm1
and Tm2, might represent an early stress response. Beyond
stabilizing the actin filaments, these tropomyosins might
protect the actin cytoskeleton from hypoxic stresses that in-
clude increased ROS. Changes in actin organization charac-
teristic of reversion of the transformed phenotype are
induced by hypoxia at 72–96 h in SH-EP neuroblastoma
cells. This is mirrored by increased organization of HMW
tropomyosin-containing filaments. However, maximum ex-
pression of HMW tropomyosins (96 h) did not correlate
with the most significant changes in the cytoskeleton
(72 h). Hence, there is no evidence that changes in tropo-
myosin expression alone can drive the observed cytoskeletal
alterations and the increased expression of HMW tropomy-
osins may be in response to their recruitment into stress
fibres. This dissociation of tropomyosin isoform expression
and actin organization is intriguing and suggests that other
mechanisms may be at work. These findings warrant fur-
ther investigation into the potential role of tropomyosins
in driving hypoxic actin reorganization.
Additional file
Additional file 1: Figure S1. Hypoxic incubation of SH-EP neuroblastoma
cells increases levels of hypoxia-inducible transcription factors, HIF-1α and
HIF-2α. SH-EP cells were incubated for 0–144 h in normoxic (20 % O2) or
hypoxic (1 % O2) conditions, before rapidly lysing cells on ice in RIPA buffer
containing a protease inhibitor cocktail. Protein lysates were separated using
SDS-PAGE and HIFs detected using anti-HIF-1α or anti-HIF-2α antibodies.
Representative immunoblots, with HIF expression clearly upregulated in
hypoxia (H) over normoxic controls (N). Cell lysates known to contain HIF-1α
and HIF-2α used as positive control (+ve). n = 3. (PDF 1900 kb)
Abbreviations
HIF: Hypoxia-inducible factor; HMW: High molecular weight; LMW: Low
molecular weight.
Competing interests
PWG is a member of the Board of, and JRS is currently employed by,
Novogen, a company which is commercializing the use of anti-tropomyosin
drugs to treat cancer. JJG and PAP declare that they have no competing
interests.
Authors’ contributions
JJG was involved in the study design, data collection, data interpretation and
drafted the manuscript. JRS and PAP were involved in the study design,
acquisition of data and interpretation of data. PWG was involved in the
study design, interpretation of data and supervision of the research group.
All authors read, revised and approved the final manuscript.
Acknowledgements
The authors would like to thank Alyce Nehme and Melissa Desouza for
technical assistance and feedback with early stages of manuscript
preparation, and Leanne Bischof, Computational Informatics Department,
CSIRO, for the development of and assistance with the linear feature
algorithm.
Author details
1Oncology Research Unit, School of Medical Sciences, UNSW Australia, Room
229, Wallace Wurth Building, Sydney, NSW 2052, Australia. 2Pancreatic Cancer
Translational Research Group, Lowy Cancer Research Centre, UNSW Australia,
Sydney, NSW 2052, Australia. 3Current address: ARC Centre of Excellence in
Convergent Bio-Nano Science and Technology, and Department of
Microbiology and Immunology, The University of Melbourne, at the Peter
Doherty Institute for Infection and Immunity, Melbourne, VIC 3010, Australia.
Received: 30 July 2015 Accepted: 9 October 2015
References
1. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and
treatment. Pediatr Clin North Am. 2008;55(1):97–120.
2. Mueller S, Matthay KK. Neuroblastoma: biology and staging. Curr Oncol Rep.
2009;11(6):431–8.
3. Howman-Giles R, Shaw PJ, Uren RF, Chung DK. Neuroblastoma and other
neuroendocrine tumors. Semin Nucl Med. 2007;37(4):286–302.
4. DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, et al.
Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor
biology, and survival. J Pediatr Hematol Oncol. 1999;21(3):181–9.
5. Haupt R, Garaventa A, Gambini C, Parodi S, Cangemi G, Casale F, et al.
Improved survival of children with neuroblastoma between 1979 and 2005:
a report of the Italian Neuroblastoma Registry. J Clin Oncol.
2010;28(14):2331–8.
6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144(5):646–74.
7. Konerding M, Fait E, Gaumann A. 3D microvascular architecture of pre-
cancerous lesions and invasive carcinomas of the colon. Br J Cancer.
2001;84(10):1354.
8. Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the
tumor microenvironment. Cancer Res. 1996;56(24):5754–7.
9. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat
Rev Cancer. 2004;4(6):437–47.
10. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid
tumor microenvironment. J Natl Cancer Inst. 2007;99(19):1441–54.
doi:10.1093/jnci/djm135.
11. Hussein D, Estlin EJ, Dive C, Makin GW. Chronic hypoxia promotes
hypoxia-inducible factor-1α–dependent resistance to etoposide and
vincristine in neuroblastoma cells. Mol Cancer Ther. 2006;5(9):2241–50.
12. Sullivan R, Paré GC, Frederiksen LJ, Semenza GL, Graham CH. Hypoxia-induced
resistance to anticancer drugs is associated with decreased senescence and
requires hypoxia-inducible factor-1 activity. Mol Cancer Ther. 2008;7(7):1961–73.
13. Ginis I, Faller DV. Hypoxia affects tumor cell invasiveness in vitro: the role of
hypoxia-activated ligand HAL1/13 (Ku86 autoantigen). Cancer Lett.
2000;154(2):163–74.
Glass et al. BMC Cancer  (2015) 15:712 Page 10 of 12
14. Jögi A, Øra I, Nilsson H, Lindeheim Å, Makino Y, Poellinger L, et al. Hypoxia
alters gene expression in human neuroblastoma cells toward an immature
and neural crest-like phenotype. Proc Natl Acad Sci U S A.
2002;99(10):7021–6.
15. Axelson H, Fredlund E, Ovenberger M, Landberg G, Påhlman S.
Hypoxia-induced dedifferentiation of tumor cells–a mechanism behind
heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol.
2005;16(4):554–63. doi:10.1016/j.semcdb.2005.03.007.
16. Jögi A, Vallon-Christersson J, Holmquist L, Axelson H, Borg Å, Påhlman S.
Human neuroblastoma cells exposed to hypoxia: induction of genes
associated with growth, survival, and aggressive behavior. Exp Cell Res.
2004;295(2):469–87.
17. Poomthavorn P, Wong SH, Higgins S, Werther GA, Russo VC. Activation of a
prometastatic gene expression program in hypoxic neuroblastoma cells.
Endocr Relat Cancer. 2009;16(3):991–1004.
18. Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic
tumour growth and progression. Nat Rev Cancer. 2011;12(1):9–22.
19. Semenza G. Hypoxia-inducible factors in physiology and medicine. Cell.
2012;148(3):399–408. doi:10.1016/j.cell.2012.01.021.
20. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a
basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.
Proc Natl Acad Sci U S A. 1995;92(12):5510–4.
21. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that
modify HIF. Sci Signal. 2001;294(5545):1337–40.
22. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted
for VHL-mediated destruction by proline hydroxylation: implications for O2
sensing. Sci Signal. 2001;292(5516):464–8.
23. Maxwell PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME,
et al. The tumour suppressor protein VHL targets hypoxia-inducible factors
for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–5.
24. Holmquist-Mengelbier L, Fredlund E, Löfstedt T, Noguera R, Navarro S,
Nilsson H, et al. Recruitment of HIF-1α and HIF-2α to common target genes
is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive
phenotype. Cancer Cell. 2006;10(5):413–23.
25. Noguera R, Fredlund E, Piqueras M, Pietras A, Beckman S, Navarro S, et al.
HIF-1α and HIF-2α are differentially regulated in vivo in neuroblastoma: high
HIF-1α correlates negatively to advanced clinical stage and tumor
vascularization. Clin Cancer Res. 2009;15(23):7130–6.
26. Chen S, Zhang M, Xing L, Wang Y, Xiao Y, Wu Y. HIF-1α contributes to
proliferation and invasiveness of neuroblastoma cells via SHH signaling. Plos
One. 2015;10(3):e0121115.
27. Stevenson RP, Veltman D, Machesky LM. Actin-bundling proteins in cancer
progression at a glance. J Cell Sci. 2012;125(5):1073–9.
28. Yamaguchi H, Condeelis J. Regulation of the actin cytoskeleton in cancer
cell migration and invasion. Biochim Biophys Acta. 2007;1773(5):642–52.
doi:10.1016/j.bbamcr.2006.07.001.
29. Böhmer R, Scharf E, Assoian RK. Cytoskeletal integrity is required
throughout the mitogen stimulation phase of the cell cycle and
mediates the anchorage-dependent expression of cyclin D1. Mol Biol
Cell. 1996;7(1):101–11.
30. Desouza M, Gunning PW, Stehn JR. The actin cytoskeleton as a sensor and
mediator of apoptosis. Bioarchitecture. 2012;2(3):75–87.
31. Gourlay CW, Ayscough KR. The actin cytoskeleton: a key regulator of
apoptosis and ageing? Nat Rev Mol Cell Biol. 2005;6(7):583–9.
32. Ingber DE, Prusty D, Sun Z, Betensky H, Wang N. Cell shape, cytoskeletal
mechanics, and cell cycle control in angiogenesis. J Biomech.
1995;28(12):1471–84.
33. Vogler M, Vogel S, Krull S, Farhat K, Leisering P, Lutz S, et al. Hypoxia
modulates fibroblastic architecture, adhesion and migration: a role for HIF-
1α in cofilin regulation and cytoplasmic actin distribution. PLoS One.
2013;8(7):1. doi:10.1371/journal.pone.0069128.
34. Gunning P, O’Neill G, Hardeman E. Tropomyosin-based regulation of the
actin cytoskeleton in time and space. Physiol Rev. 2008;88(1):1–35.
35. Greenfield NJ, Huang YJ, Swapna G, Bhattacharya A, Rapp B, Singh A, et al.
Solution NMR structure of the junction between tropomyosin molecules:
implications for actin binding and regulation. J Mol Biol. 2006;364(1):80–96.
36. Gunning PW, Schevzov G, Kee AJ, Hardeman EC. Tropomyosin isoforms:
divining rods for actin cytoskeleton function. Trends Cell Biol.
2005;15(6):333–41.
37. Helfman DM, Flynn P, Khan P, Saeed A. Tropomyosin as a regulator of
cancer cell transformation. Tropomyosin. 2008;644:124–31.
38. Stehn JR, Haass NK, Bonello T, Desouza M, Kottyan G, Treutlein H, et al. A
novel class of anticancer compounds targets the actin cytoskeleton in
tumor cells. Cancer Res. 2013;73(16):5169–82.
39. Biedler JL, Helson L, Spengler BA. Morphology and growth, tumorigenicity,
and cytogenetics of human neuroblastoma cells in continuous culture.
Cancer Res. 1973;33(11):2643–52.
40. Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS. Multiple
neurotransmitter synthesis by human neuroblastoma cell lines and clones.
Cancer Res. 1978;38(11 Part 1):3751–7.
41. Robiolio M, Rumsey WL, Wilson DF. Oxygen diffusion and mitochondrial
respiration in neuroblastoma cells. Am J Physiol Cell Physiol.
1989;256(6):C1207–C13.
42. Vindin H, Bischof L, Gunning P, Stehn J. Validation of an algorithm to
quantify changes in actin cytoskeletal organization. J Biomol Screen.
2014;19(3):354–68.
43. Golji J, Collins R, Mofrad MR. Molecular mechanics of the α-actinin rod
domain: bending, torsional, and extensional behavior. PLoS Comput Biol.
2009;5(5), e1000389.
44. Koizumi T, Nakatsuji H, Fukawa T, Avirmed S, Fukumori T, Takahashi M, et al.
The role of Actinin-4 in bladder cancer invasion. Urology. 2010;75(2):357–64.
doi:10.1016/j.urology.2009.09.037.
45. Fukushima S, Yoshida A, Honda K, Maeshima A, Narita Y, Yamada T, et al.
Immunohistochemical actinin-4 expression in infiltrating gliomas:
association with WHO grade and differentiation. Brain Tumor Pathol.
2014;31(1):11–6. doi:10.1007/s10014-013-0139-z.
46. Yamamoto S, Tsuda H, Honda K, Takano M, Tamai S, Imoto I, et al. ACTN4
gene amplification and actinin‐4 protein overexpression drive tumour
development and histological progression in a high‐grade subset of ovarian
clear‐cell adenocarcinomas. Histopathology. 2012;60(7):1073–83.
47. Rössler J, Schwab M, Havers W, Schweigerer L. Hypoxia promotes apoptosis
of human neuroblastoma cell lines with enhanced N-myc expression.
Biochem Biophys Res Commun. 2001;281(2):272–6. doi:10.1006/bbrc.2001.4342.
48. Gordan JD, Bertovrt JA, Hu C-J, Diehl JA, Simon MC. HIF-2α promotes
hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer
Cell. 2007;11(4):335–47.
49. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and
death. Nat Rev Cancer. 2002;2(10):764–76.
50. Cannito S, Novo E, Compagnone A, di Bonzo LV, Busletta C, Zamara E, et al.
Redox mechanisms switch on hypoxia-dependent epithelial–mesenchymal
transition in cancer cells. Carcinogenesis. 2008;29(12):2267–78.
51. Park S, Kim J, Kim Y. Mulberry leaf extract inhibits cancer cell stemness in
neuroblastoma. Nutr Cancer. 2012;64(6):889–98.
52. Sadee W, Yu V, Richards M, Preis P, Schwab M, Brodsky F, et al. Expression of
neurotransmitter receptors and myc protooncogenes in subclones of a
human neuroblastoma cell line. Cancer Res. 1987;47(19):5207–12.
53. Rao U, Denslow ND, Block ER. Hypoxia induces the synthesis of
tropomyosin in cultured porcine pulmonary artery endothelial cells.
Am J Physiol Lung Cell Mol Physiol. 1994;267(3):L271–L81.
54. Zimmerman LH, Levine RA, Farber HW. Hypoxia induces a specific set of
stress proteins in cultured endothelial cells. J Clin Invest. 1991;87(3):908–14.
55. Graven KK, Zimmerman LH, Dickson EW, Weinhouse GL, Farber HW.
Endothelial cell hypoxia associated proteins are cell and stress specific.
J Cell Physiol. 1993;157(3):544–54.
56. Liu L, Cash TP, Jones RG, Keith B, Thompson CB, Simon MC. Hypoxia-
induced energy stress regulates mRNA translation and cell growth. Mol Cell.
2006;21(4):521–31. doi:10.1016/j.molcel.2006.01.010.
57. Arsham AM, Howell JJ, Simon MC. A novel hypoxia-inducible factor-
independent hypoxic response regulating mammalian target of rapamycin
and its targets. J Biol Chem. 2003;278(32):29655–60.
58. Åkerfelt M, Morimoto RI, Sistonen L. Heat shock factors: integrators of cell
stress, development and lifespan. Nat Rev Mol Cell Biol. 2010;11(8):545–55.
59. Tojkander S, Gateva G, Schevzov G, Hotulainen P, Naumanen P, Martin C,
et al. A molecular pathway for myosin II recruitment to stress fibers. Curr
Biol. 2011;21(7):539–50.
60. Ishikawa R, Yamashiro S, Matsumura F. Annealing of gelsolin-severed actin
fragments by tropomyosin in the presence of Ca2+. Potentiation of the
annealing process by caldesmon. J Biol Chem. 1989;264(28):16764–70.
61. Ishikawa R, Yamashiro S, Matsumura F. Differential modulation of actin-severing
activity of gelsolin by multiple isoforms of cultured rat cell tropomyosin.
Potentiation of protective ability of tropomyosins by 83-kDa nonmuscle
caldesmon. J Biol Chem. 1989;264(13):7490–7.
Glass et al. BMC Cancer  (2015) 15:712 Page 11 of 12
62. Boyd J, Risinger JI, Wiseman RW, Merrick BA, Selkirk JK, Barrett JC. Regulation
of microfilament organization and anchorage-independent growth by
tropomyosin 1. Proc Natl Acad Sci U S A. 1995;92(25):11534–8.
63. Prasad G, Fuldner RA, Cooper HL. Expression of transduced tropomyosin 1
cDNA suppresses neoplastic growth of cells transformed by the ras
oncogene. Proc Natl Acad Sci U S A. 1993;90(15):7039–43.
64. Raval GN, Bharadwaj S, Levine EA, Willingham MC, Geary RL, Kute T, et al.
Loss of expression of tropomyosin-1, a novel class II tumor suppressor that
induces anoikis, in primary breast tumors. Oncogene. 2003;22(40):6194–203.
65. Prasad G, Masuelli L, Raj M, Harindranath N. Suppression of src-induced
transformed phenotype by expression of tropomyosin-1. Oncogene.
1999;18(11):2027–31.
66. Janssen R, Mier JW. Tropomyosin-2 cDNA lacking the 3'untranslated region
riboregulator induces growth inhibition of v-Ki-ras-transformed fibroblasts.
Mol Biol Cell. 1997;8(5):897–908.
67. Gimona M, Kazzaz JA, Helfman DM. Forced expression of tropomyosin 2 or
3 in v-Ki-ras-transformed fibroblasts results in distinct phenotypic effects.
Proc Natl Acad Sci U S A. 1996;93(18):9618–23.
68. Dalle-Donne I, Rossi R, Milzani A, Di Simplicio P, Colombo R. The actin
cytoskeleton response to oxidants: from small heat shock protein
phosphorylation to changes in the redox state of actin itself. Free Radic Biol
Med. 2001;31(12):1624–32. doi:10.1016/S0891-5849(01)00749-3.
69. Moldovan L, Moldovan NI, Sohn RH, Parikh SA, Goldschmidt-Clermont PJ.
Redox changes of cultured endothelial cells and actin dynamics. Circ Res.
2000;86(5):549–57.
70. Lassing I, Schmitzberger F, Björnstedt M, Holmgren A, Nordlund P, Schutt
CE, et al. Molecular and structural basis for redox regulation of β-actin. J Mol
Biol. 2007;370(2):331–48.
71. Liu L, Wise DR, Diehl JA, Simon MC. Hypoxic reactive oxygen species
regulate the integrated stress response and cell survival. J Biol Chem.
2008;283(45):31153–62.
72. Mansfield KD, Guzy RD, Pan Y, Young RM, Cash TP, Schumacker PT, et al.
Mitochondrial dysfunction resulting from loss of cytochrome c impairs
cellular oxygen sensing and hypoxic HIF-α activation. Cell Metab.
2005;1(6):393–9.
73. Lluis JM, Buricchi F, Chiarugi P, Morales A, Fernandez-Checa JC. Dual role of
mitochondrial reactive oxygen species in hypoxia signaling: activation of
nuclear factor-κB via c-SRC–and oxidant-dependent cell death. Cancer Res.
2007;67(15):7368–77.
74. Houle F, Rousseau S, Morrice N, Luc M, Mongrain S, Turner CE, et al.
Extracellular signal-regulated kinase mediates phosphorylation of
tropomyosin-1 to promote cytoskeleton remodeling in response to
oxidative stress: impact on membrane blebbing. Mol Biol Cell.
2003;14(4):1418–32.
75. Varga AE, Stourman NV, Zheng Q, Safina AF, Quan L, Li X, et al. Silencing of
the Tropomyosin-1 gene by DNA methylation alters tumor suppressor
function of TGF-β. Oncogene. 2005;24(32):5043–52.
76. Bharadwaj S, Prasad G. Tropomyosin-1, a novel suppressor of cellular
transformation is downregulated by promoter methylation in cancer cells.
Cancer Lett. 2002;183(2):205–13.
77. Shields JM, Mehta H, Pruitt K, Der CJ. Opposing roles of the extracellular
signal-regulated kinase and p38 mitogen-activated protein kinase cascades
in Ras-mediated downregulation of tropomyosin. Mol Cell Biol.
2002;22(7):2304–17.
78. Shahrzad S, Bertrand K, Minhas K, Coomber B. Induction of DNA
hypomethylation by tumor hypoxia. Epigenetics. 2007;2(2):119–25.
79. Schevzov G, Whittaker SP, Fath T, Lin J, Gunning PW. Tropomyosin isoforms
and reagents. Bioarchitecture. 2011;1(4):135–64.
80. Schevzov G, Vrhovski B, Bryce NS, Elmir S, Qiu MR, O'Neill GM, et al.
Tissue-specific tropomyosin isoform composition. J Histochem
Cytochem. 2005;53(5):557–70.
81. Nicholson-Flynn K, Hitchcock-DeGregori SE, Levitt P. Restricted expression of
the actin-regulatory protein, tropomyosin, defines distinct boundaries,
evaginating neuroepithelium, and choroid plexus forerunners during early
CNS development. J Neurosci. 1996;16(21):6853–63.
82. Lynch J, Somerville T, Spencer GJ, Huang X, Somervaille TC. TTC5 is required
to prevent apoptosis of acute myeloid leukemia stem cells. Cell Death Dis.
2013;4(4):e573. doi:10.1038/cddis.2013.107.
83. Shao H, Wang JH-C, Pollak MR, Wells A. α-actinin-4 is essential for
maintaining the spreading, motility and contractility of fibroblasts. PLoS
One. 2010;5(11), e13921.
84. Wong CC-L, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, et al.
Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic
niche formation. Proc Natl Acad Sci U S A. 2011;108(39):16369–74.
85. Arzenani MK, Zade AE, Ming Y, Vijverberg SJ, Zhang Z, Khan Z, et al.
Genomic DNA hypomethylation by histone deacetylase inhibition
implicates DNMT1 nuclear dynamics. Mol Cell Biol. 2011;31(19):4119–28.
86. Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, Djureinovic T,
et al. Poly (ADP-Ribose) polymerase is hyperactivated in homologous
recombination–defective cells. Cancer Res. 2010;70(13):5389–98.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Glass et al. BMC Cancer  (2015) 15:712 Page 12 of 12
